Escala Medical Secures $4.5M to Revolutionize Pelvic Organ Prolapse Treatment with Incision-Free Solutions

Escala Medical is thrilled to announce a major milestone in its journey toward revolutionizing women’s healthcare with a recent funding round of $4.5 million. Founded in November 2014, Escala Medical has consistently pursued its vision of providing disruptive, incision-free repair solutions for women suffering from Pelvic Organ Prolapse (POP). This substantial infusion of capital will accelerate the development of the world’s first minimally invasive, non-surgical, and incision-free repair solution for POP, directly addressing an unmet need in women’s health. With a solid foundation built on proven leadership, innovation, and deep clinical expertise in the field of urogynaecology, Escala Medical is uniquely positioned to transform treatment paradigms. The funding will enable the company to further invest in cutting-edge research and development, scale its promising technology from the lab to clinical settings, and accelerate the commercialization process. The goal is to provide safe, effective, and patient-friendly alternatives to traditional surgical interventions, thereby improving the quality of life for countless women facing the challenges of POP. This exciting milestone not only validates the company’s disruptive approach but also underscores the confidence that investors have in Escala’s mission to redefine care standards. By combining the experience of its leadership with a forward-thinking strategy, the company is charting a course toward a future where women can regain control of their lives without the risks associated with conventional surgery. The journey ahead is filled with promise, and Escala Medical remains committed to pushing innovation for the betterment of women's health worldwide.